ACCESSWIRE
17 Mar 2023, 16:31 GMT+10
GOTHENBURG, SWEDEN / ACCESSWIRE / March 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.
One abstract has been selected to be presented as an oral presentation during the session Symposium: Exploring new targets in AD, PD and LBD:
Three abstracts have been accepted as poster presentations and will be available to view online and onsite during the full length of the congress:
The presentations will also be available on IRLAB's website following the presentations.
For more details about the AD/PD™ 2023 congress, please visit: https://adpd.kenes.com/
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing three preclinical programs, IRL942, IRL757, and IRL1117, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
For more information
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
Attachments
IRLAB to hold four presentations at scientific congress AD/PD™ 2023
SOURCE: IRLAB Therapeutics
Get a daily dose of Chicago Chronicle news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Chicago Chronicle.
More InformationEDINBURGH, Scotland: Humza Yousaf, the first Muslim to lead a democratic western European nation, was sworn in as Scotland's new ...
WASHINGTON D.C.: Potentially hampering US efforts to arm Ukraine against Russia's invasion, rebuild local infrastructure and boost production, manufacturers of ...
WASHINGTON D.C.: After a series of high-profile incidents aboard US aircraft, several bipartisan lawmakers will again push for legislation to ...
HANOI, Vietnam: Tensions were again increasing off the coast of Vietnam as Hanoi ordered its navy to shadow a Chinese ...
In Warsaw last February, President Joe Biden condemned the lawless Russian invasion of Ukraine: "The idea that over 100,000 forces ...
TOKYO, Japan: Fears over intensifying Chinese military activity directed towards Taiwan could escalate into war have prompted Japan, the United ...
The Chicago Fire and visiting D.C. United combined for just five shots on target as they played to a scoreless ...
Jesper Boqvist scored the tiebreaking goal with 1:32 remaining in the second period as the New Jersey Devils pulled away ...
The Cincinnati Reds will close their season-opening series with the visiting Pittsburgh Pirates on Sunday, sending their third heralded second-year ...
With a playoff berth already clinched, the Cleveland Cavaliers host the Indiana Pacers on Sunday to kick off the final ...
The New York Knicks began to learn what it'll be like to play without Julius Randle on Friday night. Fortunately ...
Kyle Tucker had a pair of RBI singles to lift the host Houston Astros to a 6-4 victory over the ...